Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Micah Ostrowski

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Med (New York, N.Y.)|November 15, 2025
Metastatic prostate cancer: Clinical trials to watchGeorges Gebrael, Micah Ostrowski, Neeraj Agarwal
Therapeutic Advances in Medical Oncology|March 26, 2026
Antibody-drug conjugates in prostate cancer: current landscape and future directionsZeynep Irem Ozay, Chadi Hage Chehade, Georges Gebrael, et al.
European Urology|March 12, 2025
T-cell Engagers in Prostate CancerChadi Hage Chehade, Zeynep Irem Ozay, Micah Ostrowski, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 1, 2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumabGeorges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, et al.
Journal of Kidney Cancer and VHL|April 30, 2025
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell CarcinomaMicah Ostrowski, Yeonjung Jo, Georges Gebrael, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
JAMA Network Open|June 29, 2026
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate CancerGabriel Hooper, Yeonjung Jo, Varun Nandakumar, et al.
JAMA Network Open|April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United StatesChadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Med (New York, N.Y.)|November 15, 2025
Metastatic prostate cancer: Clinical trials to watchGeorges Gebrael, Micah Ostrowski, Neeraj Agarwal
Therapeutic Advances in Medical Oncology|March 26, 2026
Antibody-drug conjugates in prostate cancer: current landscape and future directionsZeynep Irem Ozay, Chadi Hage Chehade, Georges Gebrael, et al.
European Urology|March 12, 2025
T-cell Engagers in Prostate CancerChadi Hage Chehade, Zeynep Irem Ozay, Micah Ostrowski, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 1, 2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumabGeorges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, et al.
Journal of Kidney Cancer and VHL|April 30, 2025
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell CarcinomaMicah Ostrowski, Yeonjung Jo, Georges Gebrael, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
JAMA Network Open|June 29, 2026
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate CancerGabriel Hooper, Yeonjung Jo, Varun Nandakumar, et al.
JAMA Network Open|April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United StatesChadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
Pageof 1